1.
Eur J Gastroenterol Hepatol
; 33(1S Suppl 1): e1057-e1059, 2021 12 01.
Artículo
en Inglés
| MEDLINE
| ID: mdl-34074983
RESUMEN
Vedolizumab, an anti-integrin antibody, is effective for moderate to severe ulcerative colitis and Crohn's disease treatment with a good safety profile due to its gut selective mechanism of action. Upper respiratory tract vedolizumab adverse events are common; however, they are mild and do not require treatment withdrawal. Herein, we present a 39-year-old patient under vedolizumab treatment for ulcerative colitis who presented acute severe interstitial lung injury that necessitated vedolizumab withdrawal and systemic steroids administration.